Latest Insider Transactions at Inotiv, Inc. (NOTV)
This section provides a real-time view of insider transactions for Inotiv, Inc. (NOTV). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Inotiv, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Inotiv, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 01
2022
|
R Matthew Neff Director |
SELL
Open market or private sale
|
Direct |
1,000
-1.58%
|
$6,000
$6.12 P/Share
|
|
Nov 30
2022
|
Andrew H Baker |
SELL
Other acquisition or disposition
|
Indirect |
488,256
-21.28%
|
-
|
|
Nov 01
2022
|
R Matthew Neff Director |
SELL
Open market or private sale
|
Direct |
1,000
-0.78%
|
$21,000
$21.13 P/Share
|
|
Oct 17
2022
|
R Matthew Neff Director |
SELL
Open market or private sale
|
Direct |
1,000
-1.53%
|
$19,000
$19.1 P/Share
|
|
Sep 16
2022
|
Savanna Holdings, LLC > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
63,758
+50.0%
|
-
|
|
Sep 16
2022
|
Savanna Holdings, LLC > 10% Shareholder |
SELL
Other acquisition or disposition
|
Direct |
5,178,217
-100.0%
|
-
|
|
Sep 16
2022
|
Savanna Holdings, LLC > 10% Shareholder |
BUY
Other acquisition or disposition
|
Direct |
2,946,961
+50.0%
|
-
|
|
Sep 15
2022
|
Michael Garrett Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+33.33%
|
$23,000
$23.06 P/Share
|
|
Sep 09
2022
|
John Gregory Beattie Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
8,900
+14.69%
|
$195,800
$22.34 P/Share
|
|
Apr 01
2022
|
Gregory Cole Davis Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,275
+9.25%
|
-
|
|
Apr 01
2022
|
R Matthew Neff Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,275
+6.14%
|
-
|
|
Apr 01
2022
|
Richard Allen Johnson Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,275
+5.61%
|
-
|
|
Apr 01
2022
|
Nigel Brown Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,275
+47.55%
|
-
|
|
Apr 01
2022
|
Scott Cragg Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,275
+47.55%
|
-
|
|
Mar 31
2022
|
Fernanda Beraldi Former Gen'l Counsel & Sec'y |
BUY
Grant, award, or other acquisition
|
Direct |
2,500
+50.0%
|
-
|
|
Mar 17
2022
|
Robert Leasure Jr. President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
349,315
+23.68%
|
-
|
|
Mar 15
2022
|
James Harkness Chief Operating Officer, RMS |
BUY
Open market or private purchase
|
Direct |
38,968
+29.71%
|
$740,392
$19.29 P/Share
|
|
Feb 22
2022
|
Philip A Downing Sr. VP, Preclinical Srvcs. |
BUY
Open market or private purchase
|
Direct |
2,000
+4.53%
|
$46,000
$23.97 P/Share
|
|
Feb 18
2022
|
Michael Garrett Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+50.0%
|
$23,000
$23.5 P/Share
|
|
Feb 18
2022
|
Beth Taylor Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+5.63%
|
$115,000
$23.07 P/Share
|
|
Feb 18
2022
|
Gregory Cole Davis Director |
BUY
Open market or private purchase
|
Direct |
3,750
+4.82%
|
$82,500
$22.53 P/Share
|
|
Feb 18
2022
|
William D Pitchford Chief Human Resources Officer |
BUY
Open market or private purchase
|
Direct |
3,500
+4.39%
|
$73,500
$21.12 P/Share
|
|
Feb 18
2022
|
John Gregory Beattie Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
1,000
+2.28%
|
$23,000
$23.88 P/Share
|
|
Feb 17
2022
|
Gregory Cole Davis Director |
BUY
Open market or private purchase
|
Direct |
1,250
+3.55%
|
$25,000
$20.57 P/Share
|
|
Feb 17
2022
|
John Gregory Beattie Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
4,600
+9.92%
|
$96,600
$21.19 P/Share
|
|
Feb 17
2022
|
Robert Leasure Jr. President and CEO |
BUY
Open market or private purchase
|
Direct |
5,000
+1.72%
|
$115,000
$23.03 P/Share
|
|
Feb 17
2022
|
John E Sagartz Chief Strategy Officer |
BUY
Open market or private purchase
|
Direct |
2,506
+0.37%
|
$47,614
$19.95 P/Share
|
|
Feb 16
2022
|
John Gregory Beattie Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
5,800
+13.49%
|
$133,400
$23.71 P/Share
|
|
Feb 15
2022
|
Beth Taylor Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
40,000
+33.65%
|
-
|
|
Feb 15
2022
|
William D Pitchford Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+29.22%
|
-
|
|
Feb 15
2022
|
Robert Leasure Jr. President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
42,429
+13.15%
|
-
|
|
Feb 15
2022
|
John E Sagartz Chief Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
30,000
+4.23%
|
-
|
|
Dec 22
2021
|
Philip A Downing Sr. VP, Preclinical Srvcs. |
SELL
Open market or private sale
|
Direct |
3,057
-7.07%
|
$131,451
$43.04 P/Share
|
|
Dec 17
2021
|
William D Pitchford Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
299
+0.7%
|
-
|
|
Dec 17
2021
|
Beth Taylor Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
214
+0.55%
|
-
|
|
Nov 15
2021
|
Andrew H Baker |
SELL
Other acquisition or disposition
|
Indirect |
35,512
-83.23%
|
-
|
|
Nov 15
2021
|
Andrew H Baker |
SELL
Other acquisition or disposition
|
Indirect |
359,033
-13.53%
|
-
|
|
Nov 15
2021
|
Scott Cragg Director |
BUY
Other acquisition or disposition
|
Indirect |
378,984
+23.34%
|
-
|
|
Nov 05
2021
|
Nigel Brown Director |
BUY
Grant, award, or other acquisition
|
Direct |
440
+50.0%
|
-
|
|
Nov 05
2021
|
Scott Cragg Director |
BUY
Grant, award, or other acquisition
|
Indirect |
487,913
+50.0%
|
-
|
|
Nov 05
2021
|
Scott Cragg Director |
BUY
Grant, award, or other acquisition
|
Direct |
440
+50.0%
|
-
|
|
Nov 05
2021
|
Mark L Bibi General Counsel and Secretary |
BUY
Grant, award, or other acquisition
|
Direct |
58,134
+50.0%
|
-
|
|
Oct 22
2021
|
Philip A Downing Sr. VP, Preclinical Srvcs. |
BUY
Grant, award, or other acquisition
|
Direct |
1,087
+2.45%
|
-
|
|
Oct 22
2021
|
John Gregory Beattie Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
954
+2.95%
|
-
|
|
Oct 22
2021
|
William D Pitchford Chief Human Resources Officer |
BUY
Grant, award, or other acquisition
|
Direct |
454
+1.06%
|
-
|
|
Oct 22
2021
|
Beth Taylor Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,332
+3.33%
|
-
|
|
Oct 22
2021
|
Robert Leasure Jr. President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
7,571
+3.09%
|
-
|
|
Aug 02
2021
|
Richard Allen Johnson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+16.76%
|
$25,000
$1.4 P/Share
|
|
Jun 07
2021
|
John E Sagartz Chief Strategy Officer |
BUY
Open market or private purchase
|
Direct |
1,742
+0.27%
|
$48,776
$28.7 P/Share
|
|
May 28
2021
|
John E Sagartz Chief Strategy Officer |
BUY
Open market or private purchase
|
Direct |
2,012
+0.31%
|
$48,288
$24.78 P/Share
|